<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Blank, Fabian</dc:creator>
  <dc:creator>Fytianos, Kleanthis</dc:creator>
  <dc:creator>Seydoux, Emilie</dc:creator>
  <dc:creator>Rodriguez-Lorenzo, Laura</dc:creator>
  <dc:creator>Petri-Fink, Alke</dc:creator>
  <dc:creator>Garnier, Christophe von</dc:creator>
  <dc:creator>Rothen-Rutishauser, Barbara</dc:creator>
  <dc:date>2017</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Engineered nanoparticles (NPs) offer site-specific delivery, deposition and cellular  uptake due to their unique physicochemical properties and were shown to modulate  immune responses. The respiratory tract with its vast surface area is an attractive  target organ for innovative immunomodulatory therapeutic applications by pulmonary  administration of such NPs, enabling interactions with resident antigen-presenting cells  (APCs), such as dendritic cells and macrophages. Depending on the respiratory tract  compartment, e.g. conducting airways, lung parenchyma, or lung draining lymph  nodes, APCs extensively vary in their number, morphology, phenotype, and function.  Unique characteristics and plasticity render APC populations ideal targets for inhaled  specific immunomodulators. Modulation of immune responses may operate in different  steps of the immune cell-antigen interaction, i.e. antigen uptake, trafficking, processing,  and presentation to T cells. Meticulous analysis of the immunomodulatory potential, as  well as pharmacologic and biocompatibility testing of inhalable NPs is required to  develop novel strategies for the treatment of respiratory disorders such as allergic  asthma. The safe-by-design and characterization of such NPs requires well  coordinated interdisciplinary research uniting engineers, chemists biologists and  respiratory physicians. In this review we will focus on in vivo data available to facilitate  the design of nanocarrier-based strategies using NPs to modulate pulmonary immune  responses.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/305479</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305479/files/fin_ibn.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/s12951-016-0242-5</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Journal of Nanobiotechnology. - 2017, vol. 15, p. 6</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Interaction of biomedical nanoparticles with the pulmonary immune system</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
